STI Testing to Enhance PrEP Use in Pregnancy
Launched by BOTSWANA HARVARD AIDS INSTITUTE PARTNERSHIP · Apr 2, 2025
Trial Information
Current as of August 19, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial, titled "STI Testing to Enhance PrEP Use in Pregnancy," is being conducted in Botswana to explore whether offering testing for sexually transmitted infections (STIs) alongside HIV prevention options can help more pregnant women start and continue using PrEP (pre-exposure prophylaxis) during and after pregnancy. The study will involve about 600 pregnant women who are seeking antenatal care. Participants will be randomly selected to either receive the usual care, which does not include STI testing, or to have STI tests for common infections during their pregnancy and after they give birth. The researchers believe that providing STI testing may encourage more women to use PrEP, which can help prevent the transmission of HIV.
To be eligible for this trial, participants need to be pregnant women who identify as cis-gender, do not have HIV, and are not currently using PrEP. They should also plan to stay in the same city or town for at least nine months after delivery and be willing to receive care before and after giving birth in that location. Women who are interested in participating will need to provide informed consent, meaning they understand the study and agree to join. This trial aims to find effective ways to support pregnant women in maintaining their health and the health of their babies through proper HIV prevention strategies.
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Pregnant and seeking antenatal care
- • Self-identifying as a cis-gender woman
- • Living without HIV
- • Not currently using PrEP
- • Planning to remain in the city/town of enrolment until 9 months post-delivery.
- • Planning to receive antenatal and postnatal care in the city/town of enrolment.
- • Willing and able to provide informed consent
- Exclusion Criteria:
- • Male gender
- • Not pregnant
- • Living with HIV
- • Currently using PrEP
- • Not planning to remain in the city/town of enrolment until 9 months post-delivery
- • Not planning to receive antenatal and postnatal care in the city/town to enrolment
- • Not able or willing to provide informed consent for participation
About Botswana Harvard Aids Institute Partnership
The Botswana Harvard AIDS Institute Partnership (BHP) is a collaborative research initiative that aims to address the challenges of HIV/AIDS and related health issues in Botswana and the Southern Africa region. Established as a partnership between the Government of Botswana and Harvard University, BHP focuses on conducting innovative clinical trials, advancing biomedical research, and developing effective prevention and treatment strategies. The institute is committed to fostering local capacity building and ensuring that research findings are translated into practical applications to improve public health outcomes. Through its rigorous scientific approach and community engagement, BHP plays a pivotal role in enhancing the understanding of HIV/AIDS and contributing to global health advancements.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Gaborone, , Botswana
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported